Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 7/20 | 0.37 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | SMO | Q99835 | 2/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744513 | 1.00 | CXCR3 (0.37) | CXCR3SGPL1PTGDR2LMNASMN1; SMN2 | |
| SCHEMBL2744385 | 0.94 | CXCR3 (0.37) | CXCR3SGPL1PTGDR2LMNASMN1; SMN2 | |
| SCHEMBL2744016 | 0.94 | CXCR3 (0.37) | CXCR3SGPL1PTGDR2LMNASMN1; SMN2 | |
| SCHEMBL2744020 | 0.94 | CXCR3 (0.37) | CXCR3SGPL1PTGDR2LMNASMN1; SMN2 | |
| SCHEMBL2743711 | 0.91 | SGPL1 (0.37) | CXCR3SGPL1PTGDR2LMNASMN1; SMN2 | |
| SCHEMBL2744108 | 0.91 | SGPL1 (0.37) | CXCR3SGPL1PTGDR2LMNASMN1; SMN2 | |
| SCHEMBL2743709 | 0.91 | SGPL1 (0.37) | CXCR3SGPL1PTGDR2LMNASMN1; SMN2 | |
| SCHEMBL3674935 | 0.82 | SGPL1 (0.37) | CXCR3SGPL1PTGDR2LMNASMN1; SMN2 | |
| SCHEMBL4398201 | 0.82 | PTGDR2 (0.42) | CXCR3SGPL1PTGDR2LMNASMN1; SMN2 | |
| SCHEMBL2744023 | 0.82 | LMNA (0.37) | CXCR3SGPL1PTGDR2LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2012-08-09 | — | — | US | claimed |
| US-8178526-B2 | Compounds and compositions as ITPKb inhibitors | IRM LLC (BM) | 2012-05-15 | — | — | US | claimed |
| EP-2167498-B1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-09-15 | — | — | EP | claimed |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-07-22 | — | — | US | claimed |
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2012-08-09 | — | — | US | disclosed |
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2012-08-09 | — | — | US | disclosed |
| US-8178526-B2 | Compounds and compositions as ITPKb inhibitors | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| US-8178526-B2 | Compounds and compositions as ITPKb inhibitors | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| US-8178526-B2 | Compounds and compositions as ITPKb inhibitors | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| EP-2167498-B1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-09-15 | — | — | EP | disclosed |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | CXCR3 1157/4885SGPL1 671/4885PTGDR2 2409/4885 |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K3, IP6K2 | CXCR3 1242/4885SGPL1 569/4885PTGDR2 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.